# FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma

> **NCT02023593** · PHASE2 · COMPLETED · sponsor: **Yuhong Li** · enrollment: 35 (actual)

## Conditions studied

- Advanced Esophageal Carcinoma

## Interventions

- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT02023593
- **Lead sponsor:** Yuhong Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2019-12
- **Final completion:** 2022-12
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02023593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02023593, "FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02023593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*